MitraClip: Valve repair device offers new treatment option for some with severe mitral regurgitation

Mitral valve regurgitation (MR), a condition in which the mitral valve does not close properly, allowing blood to leak back into the heart’s upper chamber, is the most common disease of the heart valves. It can cause symptoms such as cough, fatigue, and trouble breathing. The risk of MR increases with age. Until recently, there were only two methods of treatment for MR: medication and open-heart surgery. During this surgery, the surgeon accesses the heart by opening up the breastbone. He or she either repairs or replaces the mitral valve while a heart-lung machine takes over the job of the heart and lungs while the heart is stopped. However, we now have a third option, a new device called MitraClip. What is mitral regurgitation? The heart receives blood from the lungs into the upper left chamber (the left atrium) and pumps blood to the body through the heart’s lower left chamber (the left ventricle). The mitral valve is located between these two chambers. The valve has two large leaflets — an anterior leaflet and a posterior leaflet — with parachute strings, called chords, that are attached to the heart muscle. When working normally, the leaflets open and close to move blood forward and prevent blood from returning to the left atrium when the heart contracts. When these parachute chords rupture or stretch, the leaflet prolapses, so that the valve no longer closes completely. This allows blood to leak backwards, into the left atrium, when the heart cont...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Heart Health Surgery Source Type: blogs

Related Links:

Publication date: Available online 5 June 2020Source: Meta GeneAuthor(s): Hasan Mollanoori, Yazdan Rahmati, Bita Hassani, Sajjad Esmaeili, Komail Amini, Shahram Teimourian
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
I ’ve had a fever, a cough and breathlessness since February, and been in and out of hospital. If it isn’t coronavirus, what is it? BySimon HattenstoneI ’m lying in bed, shivering like crazy. My partner, Diane, is asleep, and I burrow deep into her back. I’m sweating like crazy, too. I’m desperate for the loo, and I run there in my shivery sweats and sweaty shivers. It’s only five minutes since I last went. When I sleep, the same obsessive m oment plays again and again. It’s to do with numbers. I need to get past number nine, but I can’t. The dream lasts for hours. Finally, I...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus outbreak Infectious diseases Medical research Microbiology Science World news Health & wellbeing Boris Johnson Politics Society UK news Conservatives NHS Hospitals Doctors Source Type: news
Authors: Ali S, Sirota E, Ali H, Bezrukov E, Okhunov Z, Bukatov M, Letunovskiy A, Grygoriev N, Taratkin M, Vovdenko S, Afyouni A, Alyaev Y Abstract Objective: We sought to improve the educational and pre-operative training on various stages of percutaneous nephrolithotomy (PCNL) under fluoroscopic and ultrasound guidance. We developed a three-dimensional (3D) printed simulator (3D-printed PCNL model) for urological trainees.Methods: 40 s year urology residents were randomly assigned into two groups, completing PCNL surgical steps on a URO Mentor™ surgical simulator (Group A) or on our new 3D-printed PC...
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
Abiomed said it has received approval for an IDE to start an early feasibility study of what it is calling the “world’s smallest heart pump.”   The Danvers, MA-based company said the first-in-human trial will look at the 9 French Impella ECP heart pump in high-risk percutaneous coronary intervention (PCI) patients.   The primary endpoint of the study is successful delivery, initiation, and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI.   The stu...
Source: MDDI - Category: Medical Devices Tags: Cardiovascular Regulatory and Compliance Source Type: news
Conclusion: We describe the successful use of a simple, low risk, and technique modification of the "gasket seal" technique adapted to the clivus that allows for hard reconstruction and facilitates placement of the nasoseptal flap. PMID: 32494378 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Publication date: Available online 4 June 2020Source: Pharmacological ResearchAuthor(s): Lin Wang, Linsheng Liu, Xiaoxue Liu, Min Xiang, Ling Zhou, Chenrong Huang, Zhenya Shen, Liyan Miao
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
This study demonstrated that UCMSCs inhibited the cytotoxic effect of AGE in cells from patients with POP by inducing an anti-inflammatory reaction and activating the PI3K/AKT/PTEN signaling pathway. The current results provide important insights into use of stem cells to treat POP. PMID: 32493859 [PubMed - as supplied by publisher]
Source: BioScience Trends - Category: Biomedical Science Tags: Biosci Trends Source Type: research
Publication date: Available online 2 June 2020Source: Materials LettersAuthor(s): J.A. Hermann-Muñoz, J.A. Rincón-López, D.A. Fernández-Benavides, R. Detsch, J.M. Alvarado-Orozco, A.R Boccaccini, J. Muñoz-Saldaña
Source: Materials Letters - Category: Materials Science Source Type: research
Publication date: Available online 5 June 2020Source: Journal of Materials Science &TechnologyAuthor(s): Xiao Lin, Yanjie Bai, Huan Zhou, Lei Yang
Source: Journal of Materials Science and Technology - Category: Materials Science Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Atrial Fibrillation | Blogging | Cardiology | Contracts | Cough | Gastroschisis Repair | Harvard | Health | Heart | Heart Failure | Heart Valve Disease | Heart Valve Surgery | Heart Valves | Hospitals | Study | Ultrasound